2025 Review: Capital’s Better
The first quarter of the year got off to a predictably shaky start for a biopharma market which is marked by increasing uncertainty and turmoil. Huge cuts at the FDA, coupled with the will-they/won’t-they situation on tariffs for pharmaceutical...
Foreword
Q4 Activity Finishes Off Stronger Biopharma M&A Year In 2025
Q4 VC Fundraising Surge Not Enough For 2025 To Best Full-Year 2024 Total
Asian Offerings Again Outpace Western Biopharma IPOs In Q4
Full-Year 2025: 13 In US, Europe Vs. 20 In China, South Korea
How We Help
Get In Contact